Revision history
[SHINSA]Points to Consider for Concordance Evaluation of Companion Diagnostics Using DNA Sequencers(Early Consideration)and Points to Consider for the Development of Companion Diagnostics for Drugs with Efficacy and Safety Demonstrated in Clinical Trials in Which Patients Were Enrolled Using Tests Selected by Clinical Trial Sites(Early Consideration) posted. — 5 versions recorded. Nothing here has been overwritten.
-
[SHINSA]Points to Consider for Concordance Evaluation of Companion Diagnostics Using DNA Sequencers(Early Consideration)and Points to Consider for the Development of Companion Diagnostics for Drugs with Efficacy and Safety Demonstrated in Clinical Trials in Which Patients Were Enrolled Using Tests Selected by Clinical Trial Sites(Early Consideration) posted.
-
Version 4 imported change[SHINSA]Basic Principles for the Use of AI in Regulatory Activities(Early Consideration) posted.
-
Version 3 imported change[SHINSA]Points to Consider for the Development of Companion Diagnostics Developed in Parallel with Anti-cancer Drugs(Early Consideration) and Quality-Related Considerations for Human Cell-Derived Extracellular Vesicle (EV) Products at the Time of Initial Clinical Trial Notification (Early Consideration) posted.
-
Version 2 imported change[SHINSA]Considerations for Safety Assurance Measures in Bioequivalence Studies in Healthy Adults for the Development of Generic Drugs(Early Consideration) posted.
-
Version 1 original[SHINSA]Points to Consider for the Evaluation of the Effects of Food on the Pharmacokinetics of Oral Drug Products (Early Consideration) posted.